SGLT2 Inhibitors and Iron: More Than Meets the Eye
- PMID: 37737759
- DOI: 10.1016/j.jchf.2023.08.013
SGLT2 Inhibitors and Iron: More Than Meets the Eye
Keywords: SGLT2 inhibitors; heart failure; iron.
Conflict of interest statement
Funding Support and Author Disclosures Dr Docherty reports that his employer, the University of Glasgow, has been remunerated by AstraZeneca for work relating to clinical trials; he has received speaker honoraria from AstraZeneca, Pharmacosmos, and Radcliffe Cardiology; has served on an advisory board for Us2.ai and Bayer AG; has served on a clinical endpoint committee for Bayer AG; and has received grant support from Boehringer Ingelheim, Roche Diagnostics, and AstraZeneca (paid to his institution).
Comment on
-
Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status.JACC Heart Fail. 2023 Nov;11(11):1611-1622. doi: 10.1016/j.jchf.2023.07.010. Epub 2023 Sep 6. JACC Heart Fail. 2023. PMID: 37676213 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical